Updated HHS Adult and Adolescent Antiretroviral Treatment Guidelines Released

July 14, 2016

From AIDSinfo
  • The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents announces the release of the updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Most notably, the approval of 3 fixed-dose combination products containing tenofovir alafenamide (an oral prodrug of tenofovir) and emtricitabine (TAF/FTC) prompted several guideline updates.

    Key guideline updates include the following:

    • In the What to Start section, TAF/FTC was added as a 2-NRTI option in several Recommended and Alternative Regimens. Other updates include the addition of guidance for clinicians when choosing between ABC-, TAF-, and TDF-containing regimens and the removal of the lopinavir/ritonavir (LPV/r) plus 2-NRTI regimen from the list of Other regimens.
    • Reflecting the most current data, the Regimen Switching section was simplified to focus on switch strategies for virologically suppressed patients.
    • In the HIV and Women section, the Panel emphasizes that ART is recommended for all HIV-infected patients, including all HIV-infected women, and stresses the importance of early treatment for HIV-infected women during pregnancy and continuation of ART after pregnancy.
    • Changes to the Hepatitis B (HBV)/HIV and Hepatitis C (HCV)/HIV Coinfection sections include the addition of TAF/FTC as an option to treat HBV/HIV coinfection and updated information on interactions between ARVs and the recently approved HCV drugs daclatasvir and the fixed-dose combination elbasvir/grazoprevir.
    • A discussion on the treatment of latent tuberculosis infection (LTBI) in HIV-infected persons is now included in the Tuberculosis (TB)/HIV Coinfection section. The added discussion notes that a 12-week course of once-weekly rifapentine and isoniazid is an option for patients receiving either an efavirenz- or a raltegravir-based regimen.
This article was provided by AIDSinfo. Visit the AIDSinfo website to find out more about their activities and publications.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in Internet search results. Be careful when providing personal information! Before adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: